Astria Therapeutics (ATXS) started a phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis.
Trial is intended to evaluate safety, tolerability, pharmacokinetics and immunogenicity in 40 adults with early proof-of-concept results expected in Q3, the company said Thursday in a statement.
Price: 7.48, Change: -0.02, Percent Change: -0.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.